{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:09Z","timestamp":1788044289440,"version":"build-2784847793"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Research and Development Project of Zhejiang \"top soldiers\" and \"leading geese\"","award":["2022C03172"],"award-info":[{"award-number":["2022C03172"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2020-04-44"],"award-info":[{"award-number":["320.6750.2020-04-44"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Province Medical and Health Technology Plan Project","award":["2024KY1853"],"award-info":[{"award-number":["2024KY1853"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00228-024-03730-5","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T07:01:51Z","timestamp":1720854111000},"page":"1555-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis"],"prefix":"10.1007","volume":"80","author":[{"given":"Xing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peimin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"3","key":"3730_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000528784","volume":"9","author":"A Ortiz","year":"2023","unstructured":"Ortiz A, Portoles J, Pino-Pino MD, Barea J, L\u00f3pez M, de Sequera P, Quiroga B, Echarri R, Prieto Velasco M, D\u00edaz R, G\u00f3mez Marqu\u00e9s G, Sanchez Perez P, Torregrosa V, Rodriguez M, SAVANA Research Group, SENEFRO-BD-SHPT working group (2023) Clinical characteristics and management of patients with secondary hyperparathyroidism undergoing hemodialysis: a feasibility analysis of electronic health records using natural language processing. Kidney Dis (Basel) 9(3):187\u2013196. https:\/\/doi.org\/10.1159\/000528784","journal-title":"Kidney Dis (Basel)"},{"issue":"6","key":"3730_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ckj\/sfz021","volume":"12","author":"J Rottembourg","year":"2019","unstructured":"Rottembourg J, Ure\u00f1a-Torres P, Toledano D, Gueutin V, Hamani A, Coldefy O, Hebibi H, Guincestre T, Emery C (2019) Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. Clin Kidney J 12(6):871\u2013879. https:\/\/doi.org\/10.1093\/ckj\/sfz021","journal-title":"Clin Kidney J"},{"issue":"10","key":"3730_CR3","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/ndt\/gft514","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Ure\u00f1a-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, Larsson TE, Massy ZA, Mazzaferro S, CKD-MBD Working Group of ERA-EDTA (2014) Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant 29(10):1815\u20131820. https:\/\/doi.org\/10.1093\/ndt\/gft514","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3730_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","volume":"15","author":"FM Hannan","year":"2018","unstructured":"Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV (2018) The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 15(1):33\u201351. https:\/\/doi.org\/10.1038\/s41574-018-0115-0","journal-title":"Nat Rev Endocrinol"},{"key":"3730_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1111\/j.1523-1755.2005.09501.x","volume":"95","author":"J Silver","year":"2005","unstructured":"Silver J, Levi R (2005) Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 95:S8\u2013S12. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09501.x","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"3730_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1681\/ASN.2010020186","volume":"22","author":"R Kumar","year":"2011","unstructured":"Kumar R, Thompson JR (2011) The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 22(2):216\u2013224. https:\/\/doi.org\/10.1681\/ASN.2010020186","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3730_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5603\/ep.95820","volume":"74","author":"M Rodzo\u0144-Norwicz","year":"2023","unstructured":"Rodzo\u0144-Norwicz M, Norwicz S, Sowa-Ku\u0107ma M, Gala-B\u0142\u0105dzi\u0144ska A (2023) Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities. Endokrynol Pol 74(5):490\u2013498. https:\/\/doi.org\/10.5603\/ep.95820","journal-title":"Endokrynol Pol"},{"issue":"14","key":"3730_CR8","doi-asserted-by":"publisher","first-page":"1191914","DOI":"10.3389\/fendo.2023.1191914","volume":"22","author":"C Iorga","year":"2023","unstructured":"Iorga C, Iorga CR, Andreiana I, Bengulescu I, Constantin T, Strambu V (2023) Advantages of total parathyroidectomy in patients with secondary hyperparathyroidism induced by end stage renal disease. Front Endocrinol (Lausanne) 22(14):1191914. https:\/\/doi.org\/10.3389\/fendo.2023.1191914","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"3730_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00467-019-04400-w","volume":"35","author":"J Bacchetta","year":"2020","unstructured":"Bacchetta J (2020) Treatment of hyperphosphatemia: the dangers of high PTH levels. Pediatr Nephrol 35(3):493\u2013500. https:\/\/doi.org\/10.1007\/s00467-019-04400-w","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"3730_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00467-019-04399-0","volume":"35","author":"D Haffner","year":"2020","unstructured":"Haffner D, Leifheit-Nestler M (2020) Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels. Pediatr Nephrol 35(3):485\u2013491. https:\/\/doi.org\/10.1007\/s00467-019-04399-0","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"3730_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nrm1154","volume":"4","author":"AM Hofer","year":"2003","unstructured":"Hofer AM, Brown EM (2003) Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4(7):530\u2013538. https:\/\/doi.org\/10.1038\/nrm1154","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Suppl 5","key":"3730_CR12","doi-asserted-by":"publisher","first-page":"V20","DOI":"10.1093\/ndt\/gfh1052","volume":"19","author":"TB Dr\u00fceke","year":"2004","unstructured":"Dr\u00fceke TB (2004) Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 19(Suppl 5):V20\u2013V26. https:\/\/doi.org\/10.1093\/ndt\/gfh1052","journal-title":"Nephrol Dial Transplant"},{"issue":"14","key":"3730_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2165\/00003495-200767140-00003","volume":"67","author":"D Andress","year":"2007","unstructured":"Andress D (2007) Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 67(14):1999\u20132012. https:\/\/doi.org\/10.2165\/00003495-200767140-00003","journal-title":"Drugs"},{"issue":"Suppl 1","key":"3730_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1755-6686.2009.00066.x","volume":"35","author":"S Dusilov\u00e1-Sulkov\u00e1","year":"2009","unstructured":"Dusilov\u00e1-Sulkov\u00e1 S (2009) Vitamin D metabolism and vitamin D traditional and nontraditional, target organs: implications for kidney patients. J Ren Care 35(Suppl 1):39\u201344. https:\/\/doi.org\/10.1111\/j.1755-6686.2009.00066.x","journal-title":"J Ren Care"},{"issue":"8","key":"3730_CR15","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15(8):2208\u20132218. https:\/\/doi.org\/10.1097\/01.ASN.0000133041.27682.A2","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3730_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/1744-9987.12434","volume":"20","author":"\u017d Ve\u010deri\u0107-Haler","year":"2016","unstructured":"Ve\u010deri\u0107-Haler \u017d, Romozi K, Antoni\u010d M, Benedik M, Ponikvar JB, Ponikvar R, Knap B (2016) Comparison of the pharmacological effects of paricalcitol versus calcitriol on secondary hyperparathyroidism in the dialysis population. Ther Apher Dial 20(3):261\u2013266. https:\/\/doi.org\/10.1111\/1744-9987.12434","journal-title":"Ther Apher Dial"},{"issue":"4","key":"3730_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11255-015-1195-6","volume":"48","author":"P Cai","year":"2016","unstructured":"Cai P, Tang X, Qin W, Ji L, Li Z (2016) Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol 48(4):571\u2013584. https:\/\/doi.org\/10.1007\/s11255-015-1195-6","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"3730_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/1744-9987.12760","volume":"23","author":"T Zhang","year":"2019","unstructured":"Zhang T, Ju H, Chen H, Wen W (2019) Comparison of paricalcitol and calcitriol in dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled studies. Ther Apher Dial 23(1):73\u201379. https:\/\/doi.org\/10.1111\/1744-9987.12760","journal-title":"Ther Apher Dial"},{"issue":"1","key":"3730_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-019-1639-9","volume":"21","author":"Y Sun","year":"2020","unstructured":"Sun Y, Tian B, Sheng Z, Wan P, Xu T, Yao L (2020) Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis. BMC Nephrol 21(1):316. https:\/\/doi.org\/10.1186\/s12882-019-1639-9","journal-title":"BMC Nephrol"},{"issue":"1","key":"3730_CR20","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41598-018-21397-8","volume":"8","author":"G Wang","year":"2018","unstructured":"Wang G, Liu H, Wang C, Ji X, Gu W, Mu Y (2018) Cinacalcet versus placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. Sci Rep 8(1):3111. https:\/\/doi.org\/10.1038\/s41598-018-21397-8","journal-title":"Sci Rep"},{"issue":"11","key":"3730_CR21","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s11255-019-02271-6","volume":"51","author":"J Xu","year":"2019","unstructured":"Xu J, Yang Y, Ma L, Fu P, Peng H (2019) Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials. Int Urol Nephrol 51(11):2027\u20132036","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"3730_CR22","doi-asserted-by":"publisher","first-page":"e48070","DOI":"10.1371\/journal.pone.0048070","volume":"7","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Li M, You L, Li H, Ni L, Gu Y, Hao C, Chen J (2012) Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS ONE 7(10):e48070. https:\/\/doi.org\/10.1371\/journal.pone.0048070","journal-title":"PLoS ONE"},{"issue":"40","key":"3730_CR23","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.2174\/1381612829666221027110656","volume":"28","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang Q, Chen G, Zhou T (2022) A systematic review and meta-analysis of efficacy and safety of calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Curr Pharm Des 28(40):3289\u20133304. https:\/\/doi.org\/10.2174\/1381612829666221027110656","journal-title":"Curr Pharm Des"},{"issue":"1","key":"3730_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12020-012-9711-2","volume":"43","author":"D Li","year":"2013","unstructured":"Li D, Shao L, Zhou H, Jiang W, Zhang W, Xu Y (2013) The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine 43(1):68\u201377. https:\/\/doi.org\/10.1007\/s12020-012-9711-2","journal-title":"Endocrine"},{"issue":"1","key":"3730_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, Prieto-Alhambra D, Torres PU, Cannata-Andia J, European Renal Osteodystrophy (EUROD) workgroup, An initiative of the CKD-MBD working group of the ERA-EDTA, The committee of Scientific Advisors and National Societies of the IOF (2021) European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D. Nephrol Dial Transplant 36(1):42\u201359. https:\/\/doi.org\/10.1093\/ndt\/gfaa192","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3730_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jocd.2019.03.004","volume":"24","author":"CH Wu","year":"2021","unstructured":"Wu CH, Chang YF, Chen CH, Lewiecki EM, W\u00fcster C, Reid I, Tsai KS, Matsumoto T, Mercado-Asis LB, Chan DC, Hwang JS, Cheung CL, Saag K, Lee JK, Tu ST, Xia W, Yu W, Chung YS, Ebeling P, Mithal A, Ferrari SL, Cooper C, Lin GT, Yang RS (2021) Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the asia-pacific region. J Clin Densitom 24(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jocd.2019.03.004","journal-title":"J Clin Densitom"},{"issue":"24","key":"3730_CR27","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","volume":"56","author":"K Nitta","year":"2017","unstructured":"Nitta K, Yajima A, Tsuchiya K (2017) Management of osteoporosis in chronic kidney disease. Intern Med 56(24):3271\u20133276. https:\/\/doi.org\/10.2169\/internalmedicine.8618-16","journal-title":"Intern Med"},{"issue":"5","key":"3730_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, Subramanian R, Tomlinson JE (2015) Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 88(5):853\u2013865. https:\/\/doi.org\/10.1124\/mol.115.098392","journal-title":"Mol Pharmacol"},{"issue":"4","key":"3730_CR29","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299(4):F882\u2013F889. https:\/\/doi.org\/10.1152\/ajprenal.00360.2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"3730_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0272-6386(04)00817-0","volume":"44","author":"T Sato","year":"2004","unstructured":"Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M (2004) Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44(3):481\u2013487","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"3730_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/hdi.12410","volume":"20","author":"C Mei","year":"2016","unstructured":"Mei C, Chen N, Ding X, Yu X, Wang L, Qian J, Wang M, Jiang G, Li X, Hou F, Zuo L, Wang N, Liu H (2016) Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis. Hemodial Int 20(4):589\u2013600. https:\/\/doi.org\/10.1111\/hdi.12410","journal-title":"Hemodial Int"},{"issue":"2","key":"3730_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317(2):156\u2013164. https:\/\/doi.org\/10.1001\/jama","journal-title":"JAMA"},{"issue":"15","key":"3730_CR33","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Dr\u00fceke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516\u20131525. https:\/\/doi.org\/10.1056\/NEJMoa031633","journal-title":"N Engl J Med"},{"issue":"1","key":"3730_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12882-021-02312-2","volume":"22","author":"H Eddington","year":"2021","unstructured":"Eddington H, Chinnadurai R, Alderson H, Ibrahim ST, Chrysochou C, Green D, Erekosima I, Hutchison A, Bubtana A, Hegarty J, Kalra PA (2021) A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC Nephrol 22(1):106. https:\/\/doi.org\/10.1186\/s12882-021-02312-2","journal-title":"BMC Nephrol"},{"issue":"3","key":"3730_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16(3):800\u2013807. https:\/\/doi.org\/10.1681\/ASN.2004060512","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3730_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.asn.0000050224.03126.ad","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14(3):575\u2013583. https:\/\/doi.org\/10.1097\/01.asn.0000050224.03126.ad","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3730_CR37","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfu011","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S (2014) Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant 29(4):899\u2013905. https:\/\/doi.org\/10.1093\/ndt\/gfu011","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"3730_CR38","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S (2012) Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 27(8):3270\u20133278. https:\/\/doi.org\/10.1093\/ndt\/gfs018","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"3730_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94(4):818\u2013825. https:\/\/doi.org\/10.1016\/j.kint.2018.05.013","journal-title":"Kidney Int"},{"issue":"5","key":"3730_CR40","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","volume":"28","author":"P Ure\u00f1a-Torres","year":"2013","unstructured":"Ure\u00f1a-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A (2013) Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant 28(5):1241\u20131254. https:\/\/doi.org\/10.1093\/ndt\/gfs568","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"3730_CR41","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26(4):1327\u20131339. https:\/\/doi.org\/10.1093\/ndt\/gfq725","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3730_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/0886022X.2018.1562356","volume":"41","author":"P Susantitaphong","year":"2019","unstructured":"Susantitaphong P, Vadcharavivad S, Susomboon T, Singhan W, Dumrongpisutikul N, Jakchairoongruang K, Eiam-Ong S, Praditpornsilpa K (2019) The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail 41(1):326\u2013333. https:\/\/doi.org\/10.1080\/0886022X.2018.1562356","journal-title":"Ren Fail"},{"issue":"5","key":"3730_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1440-1797.2008.01058.x","volume":"14","author":"AH Abdul Gafor","year":"2009","unstructured":"Abdul Gafor AH, Saidin R, Loo CY, Mohd R, Zainudin S, Shah SA, Norella KC (2009) Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton) 14(5):488\u2013492. https:\/\/doi.org\/10.1111\/j.1440-1797.2008.01058.x","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"3730_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1744-9987.2008.00556.x","volume":"12","author":"T Akiba","year":"2008","unstructured":"Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S, KRN1493 Study Group (2008) Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 12(2):117\u201325. https:\/\/doi.org\/10.1111\/j.1744-9987.2008.00556.x","journal-title":"Ther Apher Dial"},{"issue":"6","key":"3730_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1744-9987.2011.00994.x","volume":"15","author":"EM El-Shafey","year":"2011","unstructured":"El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M (2011) Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 15(6):547\u2013555. https:\/\/doi.org\/10.1111\/j.1744-9987.2011.00994.x","journal-title":"Ther Apher Dial"},{"issue":"1","key":"3730_CR46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S, KRN1493 study group (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23(1):328\u2013335. https:\/\/doi.org\/10.1093\/ndt\/gfm534","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3730_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Mac\u00e1rio F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Fraz\u00e3o JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3(1):36\u201345. https:\/\/doi.org\/10.2215\/CJN.03591006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3730_CR48","doi-asserted-by":"publisher","first-page":"e0118174","DOI":"10.1371\/journal.pone.0118174","volume":"10","author":"E Riccio","year":"2015","unstructured":"Riccio E, Sabbatini M, Bruzzese D, Capuano I, Migliaccio S, Andreucci M, Pisani A (2015) Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS ONE 10(3):e0118174. https:\/\/doi.org\/10.1371\/journal.pone.0118174","journal-title":"PLoS ONE"},{"issue":"5 Suppl 5","key":"3730_CR49","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","volume":"38","author":"SM Sprague","year":"2001","unstructured":"Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D (2001) Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38(5 Suppl 5):S51\u2013S56. https:\/\/doi.org\/10.1053\/ajkd.2001.28110","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3730_CR50","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, Huang S, Martin KJ, Block GA (2015) A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 31(5):943\u2013952. https:\/\/doi.org\/10.1185\/03007995.2015.1031731","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"3730_CR51","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/ndt\/gfw408","volume":"32","author":"M Fukagawa","year":"2017","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, Odani M, Akizawa T, ONO-5163 Study Group (2017) A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32(10):1723\u20131730. https:\/\/doi.org\/10.1093\/ndt\/gfw408","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"3730_CR52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2217\/cer-2018-0015","volume":"7","author":"G Lozano-Ortega","year":"2018","unstructured":"Lozano-Ortega G, Waser N, Bensink ME, Goring S, Bennett H, Block GA, Chertow GM, Trotman ML, Cooper K, Levy AR, Belozeroff V (2018) Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. J Comp Eff Res 7(7):693\u2013707. https:\/\/doi.org\/10.2217\/cer-2018-0015","journal-title":"J Comp Eff Res"},{"key":"3730_CR53","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1):1\u201359. \nhttps:\/\/doi.org\/10.1016\/j.kisu.2017.04.001. Epub 2017 Jun 21. Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1. \nhttps:\/\/doi.org\/10.1016\/j.kisu.2017.10.001","DOI":"10.1016\/j.kisu.2017.04.001 10.1016\/j.kisu.2017.10.001"},{"issue":"3 Suppl 1","key":"3730_CR54","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","volume":"76","author":"TA Ikizler","year":"2020","unstructured":"Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, Fouque D, Friedman AN, Ghaddar S, Goldstein-Fuchs DJ, Kaysen GA, Kopple JD, Teta D, Yee-Moon Wang A, Cuppari L (2020) KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis 76(3 Suppl 1):S1\u2013S107. https:\/\/doi.org\/10.1053\/j.ajkd.2020.05.006","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"3730_CR55","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2215\/CJN.06910714","volume":"10","author":"I Bhan","year":"2015","unstructured":"Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, Ankers E, Wenger J, Tucker JK, Trottier C, Pathan F, Kalim S, Nigwekar SU, Thadhani R (2015) Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 10(4):611\u2013619. https:\/\/doi.org\/10.2215\/CJN.06910714","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3730_CR56","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1681\/ASN.2015040468","volume":"27","author":"DC Miskulin","year":"2016","unstructured":"Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, Weiner DE (2016) Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial. J Am Soc Nephrol 27(6):1801\u20131810. https:\/\/doi.org\/10.1681\/ASN.2015040468","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3730_CR57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3945\/ajcn.112.040642","volume":"96","author":"JA Alvarez","year":"2012","unstructured":"Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K, Wasse H, Guti\u00e9rrez OM, Ziegler TR, Tangpricha V (2012) High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 96(3):672\u2013679. https:\/\/doi.org\/10.3945\/ajcn.112.040642","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"3730_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/ejcn.2012.217","volume":"67","author":"JA Alvarez","year":"2013","unstructured":"Alvarez JA, Zughaier SM, Law J, Hao L, Wasse H, Ziegler TR, Tangpricha V (2013) Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 67(3):264\u2013269. https:\/\/doi.org\/10.1038\/ejcn.2012.217","journal-title":"Eur J Clin Nutr"},{"issue":"9","key":"3730_CR59","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2215\/CJN.12761211","volume":"7","author":"LA Armas","year":"2012","unstructured":"Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R (2012) 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 7(9):1428\u20131434. https:\/\/doi.org\/10.2215\/CJN.12761211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3730_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4158\/EP.14.1.10","volume":"14","author":"P Chandra","year":"2008","unstructured":"Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V (2008) Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 14(1):10\u201317. https:\/\/doi.org\/10.4158\/EP.14.1.10","journal-title":"Endocr Pract"},{"issue":"7","key":"3730_CR61","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/ndt\/gft001","volume":"28","author":"P Delanaye","year":"2013","unstructured":"Delanaye P, Weekers L, Warling X, Moonen M, Smelten N, M\u00e9dart L, Krzesinski JM, Cavalier E (2013) Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 28(7):1779\u20131786. https:\/\/doi.org\/10.1093\/ndt\/gft001","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"3730_CR62","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2215\/CJN.02840312","volume":"8","author":"NA Hewitt","year":"2013","unstructured":"Hewitt NA, O\u2019Connor AA, O\u2019Shaughnessy DV, Elder GJ (2013) Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 8(7):1143\u20131149. https:\/\/doi.org\/10.2215\/CJN.02840312","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3730_CR63","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clnu.2016.05.012","volume":"36","author":"DR Mager","year":"2017","unstructured":"Mager DR, Jackson ST, Hoffmann MR, Jindal K, Senior PA (2017) Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: results of an open label randomized clinical trial. Clin Nutr 36(3):686\u2013696. https:\/\/doi.org\/10.1016\/j.clnu.2016.05.012","journal-title":"Clin Nutr"},{"issue":"9","key":"3730_CR64","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1093\/ndt\/gfs138","volume":"27","author":"P Marckmann","year":"2012","unstructured":"Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, Nybo M, Rasmussen LM, Hansen D, Scholze A (2012) Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 27(9):3523\u20133531. https:\/\/doi.org\/10.1093\/ndt\/gfs138","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3730_CR65","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.ajkd.2014.04.020","volume":"64","author":"A Massart","year":"2014","unstructured":"Massart A, Debelle FD, Racap\u00e9 J, Gervy C, Husson C, Dhaene M, Wissing KM, Nortier JL (2014) Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial. Am J Kidney Dis 64(5):696\u2013705. https:\/\/doi.org\/10.1053\/j.ajkd.2014.04.020","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3730_CR66","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.clnu.2016.04.014","volume":"35","author":"MS Meireles","year":"2016","unstructured":"Meireles MS, Kamimura MA, Dalboni MA, de Carvalho JTG, Aoike DT, Cuppari L (2016) Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: a randomized controlled trial. Clin Nutr 35(6):1251\u20131258. https:\/\/doi.org\/10.1016\/j.clnu.2016.04.014","journal-title":"Clin Nutr"},{"issue":"2","key":"3730_CR67","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00394-015-1106-8","volume":"56","author":"E Seibert","year":"2017","unstructured":"Seibert E, Lehmann U, Riedel A, Ulrich C, Hirche F, Brandsch C, Dierkes J, Girndt M, Stangl GI (2017) Vitamin D3 supplementation does not modify cardiovascular risk profile of adults with inadequate vitamin D status. Eur J Nutr 56(2):621\u2013634. https:\/\/doi.org\/10.1007\/s00394-015-1106-8","journal-title":"Eur J Nutr"},{"issue":"12","key":"3730_CR68","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1093\/ndt\/gfn367","volume":"23","author":"F Tokmak","year":"2008","unstructured":"Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC (2008) High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23(12):4016\u20134020. https:\/\/doi.org\/10.1093\/ndt\/gfn367","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3730_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/cpdd.1328","volume":"13","author":"FY Zheng","year":"2024","unstructured":"Zheng FY, Tan YY, Zhou JJ (2024) Effect of paricalcitol combined with cinacalcet on calcium and phosphorus metabolism in patients receiving maintenance hemodialysis. Clin Pharmacol Drug Dev 13(1):96\u2013102. https:\/\/doi.org\/10.1002\/cpdd.1328","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"3730_CR70","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.3892\/etm.2020.9044","volume":"20","author":"W Xu","year":"2020","unstructured":"Xu W, Gong L, Lu J, Tang W (2020) Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: a meta-analysis. Exp Ther Med 20(4):3237\u20133243. https:\/\/doi.org\/10.3892\/etm.2020.9044","journal-title":"Exp Ther Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03730-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T02:10:47Z","timestamp":1726107047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03730-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3730"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03730-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}